Kura Oncology Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
123
- Stock Symbol
-
KURA
- Investments
-
1
- Share Price
-
$16.23
- (As of Friday Closing)
Kura Oncology General Information
Description
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 12730 High Bluff Drive
- Suite 400
- San Diego, CA 92130
- United States
+1 (858) 000-0000
Kura Oncology Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.23 | $16.00 | $10.41 - $21.19 | $1.07B | 66.9M | 797K | -$2.00 |
Kura Oncology Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 740,425 | 395,689 | 1,846,703 | 380,451 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (134,144) | (130,700) | (91,705) | (67,479) |
| Net Income | (133,331) | (130,466) | (89,625) | (63,140) |
| Total Assets | 471,425 | 534,051 | 647,212 | 241,972 |
| Total Debt | 5,892 | 6,875 | 14,977 | 7,752 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kura Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kura Oncology Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics
Biotechnology
San Diego, CA
123
As of 2022
00000
00000000
00000
000000
t aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse ci
000000000000000
Cambridge, MA
00
As of 0000
00000
00000000
00000
000000
eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
0000 000000000
Cambridge, MA
00
As of 0000
00000
00000000
00000
Add Comparison
Kura Oncology Competitors (30)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Infinity Pharmaceuticals | Formerly PE-Backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000 000000 | Venture Capital-Backed | Barcelona, Spain | 00 | 0000 | 000000000000 | 0000 |
| 00000 000000000000 | Formerly VC-backed | Watertown, MA | 000 | 00.000 | 00000000 | 00.000 |
| 0000000 0000000000 | Corporation | Framingham, MA | 0 | 000.00 | 000000000 | 000.00 |
Kura Oncology Patents
Kura Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3124616-A1 | Therapies for squamous cell carcinomas | Pending | 21-Dec-2018 | 0000000000 | |
| AU-2019403379-A1 | Therapies for squamous cell carcinomas | Pending | 21-Dec-2018 | 0000000000 | |
| US-20220071941-A1 | Therapies for squamous cell carcinomas | Pending | 21-Dec-2018 | 00000000000 | |
| EP-3897638-A1 | Therapies for squamous cell carcinomas | Pending | 21-Dec-2018 | 0000000000 | |
| JP-2022514654-A | Treatment for squamous cell carcinoma | Pending | 21-Dec-2018 | A61K31/223 |
Kura Oncology Executive Team (16)
Kura Oncology Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carol Schafer | Kura Oncology | Board Member | 000 0000 |
| Diane Parks | Self | Board Member | 000 0000 |
| Faheem Hasnain | Self | Board Member | 000 0000 |
| Mary Szela | Self | Board Member | 000 0000 |
| Steven Stein MD | Self | Board Member | 000 0000 |
Kura Oncology Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kura Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kura Oncology Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000 00000000 | 06-Mar-2015 | 0000000000 | Holding Companies |